Roger joined the Ozgene team in May 2015 as our Senior Scientific Director in North America. He is based in Boston, MA. Roger comes to us with 20 years of industry experience developing and phenotyping genetically engineered models (GEMs) in collaborative support of the Therapeutic Areas (TAs) at three pharmaceutical companies.

Roger received his PhD from Wesleyan University, Department of Molecular Biology and Biochemistry and spent his postdoctoral days at the University of Cincinnati Medical School in the laboratories or Drs Jerry Lingrel and Thomas Doetschman, where he developed the gene-targeted ‘Tag-and-Exchange’ strategy for knocking in subtle mutations, including point mutations, into the mouse genome.

Roger’s pharmaceutical career started at Wyeth Pharmaceuticals, where he established the gene targeting core and managed the Molecular Genetics Department supporting all Wyeth TAs. Next, Roger joined Merck & co, where he managed and outsourced GEM development and phenotyping, supporting the Diabetes and Bone & Endocrinology pipelines. Most recently, he established Biogen’s GEM Center, supporting Neurology, Immunology, Tissue Injury and Fibrosis TAs.

Roger is an integral part of our Strategic Partnering team and enthusiastically engages with scientists from all areas. Please feel free to contact him to plan a hike in the high Sierras or to brainstorm genetically engineered models and the characterisation/phenotyping of your GEMs of interest.